brain/
sourcestock-market

Eli Lilly checkpoints: Q3, Foundayo, BLA, Bridge

LLY last-price, Q3 date, FDA classification, Foundayo mix if primary, Bridge denominator.

Source

Eli Lilly checkpoints: Q3, Foundayo, BLA, Bridge

Generated by Grok Bot research on 2026-08-31. Parallel-deep-research + native X. Treat as raw material — review before promoting into a project or thread.

Not a trade. Not a paper sleeve. No buy/sell/size. Future-map checkpoints + last-price + empty Gage slot for eli-lilly. Do not recap Q2. Do not expand or skip orexin-franchise-to-lly-glp1-playbook-repeat (leave the 2026-07-10 hypothesis as filed). Attach hardware (WST/STVN) — do not flatten it into this clip. Filer: add the confirmed Q3 date to vault/projects/stock-market/EARNINGS.md.

Summary

NYSE: LLY last close retrieved is $1,174.61 on Friday 2026-08-28 (not 2026-08-29 — that date is a Saturday). StockAnalysis LLY history prints the session as "At close: Aug 28, 2026, 4:00 PM EDT." Q3 2026 earnings call is confirmed on Lilly IR as October 29, 2026 at 10:00 AM EDT; EARNINGS.md currently lists the ticker without a dated next-report hint. Retatrutide US filing remains a planned BLA in Q1 2027 on Lilly paper, while the live FDA fight is BLA vs NDA: S.D. Ind. upheld FDA that retatrutide is not a "protein" and vacated/remanded the "analogous to a protein" finding — classification delay is the break. Foundayo mix is on the Q2 call, not the 8-K: ~1-in-4 new starts oral, ~80% of people getting treatment injectable. Bridge window is CMS 2026-07-01 through 2027-12-31; the 3.8M figure is KFF 2023 claims, not a CMS headcount; Ricks's 20 million / 35% more coverage is a Lilly call print of a different denominator. Actual Bridge script counts: none-found on a CMS or Lilly primary retrieved for this clip.

Findings

Last-price as-of (citable close)

  • As-of: Friday 2026-08-28, 4:00 PM EDT close.
  • Print: $1,174.61 (open 1,172.66 / high 1,180.00 / low 1,162.93 / volume 2,445,738) on StockAnalysis LLY price history.
  • Date check: The ask preferred "Friday 2026-08-29." 2026-08-29 is Saturday. The last NYSE session before this clip is Friday 2026-08-28. Do not invent an 08-29 close.
  • Entity eli-lilly.md currently has no last-price and no checkpoint map (updated through the 2026-08-05 Q2 ingest). This is the last-price to stamp.

Q3 call — listed vs confirmed

  • Confirmed (IR primary): Lilly IR event page "Q3 2026 Earnings Call" — "October 29, 2026 at 10:00 AM EDT." Schema.org on the same page: "name": "Q3 2026 Earnings Call", "startDate": "October 29, 2026". Retrieved 2026-08-31.
  • Listed (wiki, not dated): vault/projects/stock-market/EARNINGS.md Active watchlist line is - LLY — Eli Lilly · healthcare / GLP-1 with no next-report hint (file updated: 2026-08-21). Contrast MU, which carries "Q3 FY2026 expected late June 2026."
  • Filer action: add the confirmed date/time + IR URL to EARNINGS.md. This clip does not write that file.

Retatrutide — planned BLA Q1 2027 vs live FDA classification fight

Lilly still says BLA, Q1 2027.

  • Lilly 8-K (Item 2.02) filed 2026-08-05 furnishes Exhibit 99.1.
  • Exhibit 99.1 / Q2 2026 earnings release: "plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027." Same sentence in the Lilly IR earnings release retrieved 2026-08-31.
  • Lilly PR 2026-07-23 (PR Newswire / TRIUMPH-2 and TRIUMPH-3): "Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027" and is "completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA)."
  • Q2 FY2026 call transcript (Motley Fool, call 2026-08-05): Daniel Skovronsky — "plan to submit in the U.S. in quarter 1 2027 under the BLA pathway." Dave Ricks, asked about the BLA vs FDA determination: "we believe retatrutide is a biologic application, both in terms of amino acid count rule as well as analogous to a protein. … There was a mixed decision in the — first decision in the court. Obviously, it's an active litigation, but we would hope to come to a conclusion with the FDA to support a BLA application. … we do need to gather a little bit more on the CMC side. … look forward to the submission by Q1 next year."

FDA / court primary on the classification fight (retrieved).

  • S.D. Ind. Order on Cross-Motions for Summary Judgment, Eli Lilly and Company v. Kennedy et al., No. 1:24-cv-01503-TWP-KMB (govinfo PDF), SO ORDERED 9/30/2025:
    • FDA letter of designation 2024-03-18 classified retatrutide as a drug, not a biological product: "not an alpha amino acid polymer with a specific defined sequence greater than 40 amino acids in size"; "at most … 40 alpha amino acids and 1 non-alpha amino acid."
    • Court: FDA's decision that retatrutide is not a "protein" under 21 C.F.R. § 600.3(h)(6) is upheld.
    • Court: FDA's decision that retatrutide is not "analogous" to a protein is VACATED and REMANDED — FDA's "bright line" approach "flouts the statutory text"; agency must "identify, in a uniform fashion, the fundamental defining feature of 'analogous' proteins." The court explicitly leaves open that FDA "could lawfully reach the same conclusion" after a reasoned redo.
  • Break (classification delay): a BLA that FDA will not file-accept is an NDA slip. Lilly is still building a BLA/CMC package while the analogous-to-protein question is on remand and Ricks still calls the litigation active as of 2026-08-05. That is the checkpoint, not a re-score of TRIUMPH efficacy.
  • Appeal calendar (not load-bearing): secondary legal commentary reports a Seventh Circuit appeal and a 2026-09-24 argument date. Not retrieved from PACER, CourtListener docket for this appeal, or ca7.uscourts.gov calendar. Do not stamp 2026-09-24 as confirmed. What is retrieved: the district-court split + Ricks "active litigation."

Foundayo mix — primary retrieved (call), not 8-K

Found, on the Q2 call — not in Exhibit 99.1.

  • Motley Fool Q2 FY2026 transcript, Ilya Yuffa on US Foundayo: "we're starting to see new starts coming in nearly around 1 out of 4 starting on Foundayo."
  • Same transcript, Yuffa on Bridge/inflection mix: "we're seeing a significant preference towards injectable, probably around 80% of people that are getting treatment are injectable, but we're seeing new patients for both. And we approximate around 60% to 70% being new people that are coming in that have not had access before."
  • Same transcript, Lucas Montarce prepared remarks: "injectable incretins continue to be an important growth driver, and account for 3 out of 4 new patient starts."
  • 8-K / Exhibit 99.1 does not print the 25% / 80% mix. Exhibit 99.1 prints Foundayo $98 million Q2 revenue (first quarter as a Key Product) and US price −3% / volume +37%. Use the call for mix; use the 8-K for dollars and US price/volume.

IQVIA / prescription print for this mix: none-found. No IQVIA table or 8-K script feed was retrieved that independently prints "~25% of new starts / ~80% of treated still injectable." Do not launder sell-side IQVIA notes as a primary.

Medicare GLP-1 Bridge — window vs two denominators vs scripts

Window (CMS primary, retrieved).

  • CMS Medicare GLP-1 Bridge: demonstration "between July 1, 2026, and December 31, 2027"; $50 copay; operates outside Part D coverage/payment flow. Page last modified 2026-07-13 on the overview; Information for Providers last modified 2026-08-06.
  • Covered products on the provider FAQ (updated 2026-04-06): Foundayo, Wegovy (injection and tablets), Zepbound KwikPen only (vial and single-dose pen not in Bridge).
  • CMS has not published an eligible-headcount on the pages retrieved. KFF 2026-06-29 states that fact in words: "CMS has not released an estimate of how many beneficiaries could be eligible … although the director of Medicare at CMS, Chris Klomp, recently stated the agency anticipates the program will start with 'single-digit millions' of beneficiaries."

Print A — KFF 3.8 million (Bridge-eligible after exclusions, 2023 claims).

  • KFF 2026-06-29: among 47.5 million 2023 Part D enrollees, 9.7 million met clinical criteria; 3.8 million (39%) met clinical criteria and lacked T2D / OSA / MASH diagnoses and lacked a Part D GLP-1 fill — 8% of Part D, 7% of A/B. This is KFF's 2023 RIF analysis, not a CMS census. Wiki eli-lilly.md currently attributes "~3.8 million" to CMS. Correct the attribution on ingest: 3.8M is KFF, not CMS.

Print B — Lilly/Ricks 20 million / 35% more coverage (different denominator).

  • Q2 call, Dave Ricks prepared remarks: "the Medicare GLP-1 Bridge program launched on July 1, granting 20 million eligible Americans insurance coverage for GLP-1s for obesity at the low out-of-pocket price of $50 per month. With this expansion, 35% more people now have coverage for our obesity medicines in the United States."
  • Yuffa on the same call: "increasing access to about 35% more Americans being able to access obesity therapy."
  • These are Lilly figures. They read as clinical-criteria / coverage-expansion, not KFF's narrower Bridge-eligible-after-Part-D-exclusions 3.8M. Do not collapse 20M and 3.8M into one number.

Actual Bridge scripts: none-found.

  • No CMS utilization table, no Lilly 8-K script count, no IQVIA Bridge-tagged print was retrieved. CMS told plans (secondary reports of an 2026-08-05 memo) it will share monthly utilization with Part D sponsors this fall; that memo itself was not retrieved. Yuffa's qualitative "inflection" / 80% injectable / 60–70% new-to-treatment is call color, not a script census. Track actual Bridge fills only when a primary appears.

Confirm tests (do not re-score Q2)

Hold these as dated tests, not a quarter recap:

  1. Volume still offsets guided 3% US price decline. Exhibit 99.1: US revenue +33% on +37% volume and −3% realized price (ex-adjustments ~−9%). Q2 call, Lucas Montarce on CVS/formulary: "expect that price will actually go down … we are going to more than offset that with volume growth." Test at Q3 (2026-10-29): US volume vs realized price, and whether the offset still holds after the Q2 rebate-estimate one-offs drop out.
  2. Foundayo mix up without ASP collapse. Call: ~1-in-4 new starts on Foundayo; ~80% of treated still injectable. 8-K: Foundayo $98M. No Foundayo-specific ASP series was retrieved. Test: mix can rise if new patients (Yuffa 60–70% new-to-treatment on the Bridge inflection) rather than cannibalizing injectable ASP. Watch Q3 mix and US realized price on Zepbound/Mounjaro, not a blended "GLP-1 ASP" invention.
  3. BLA path intact. Lilly still says BLA, Q1 2027 on 8-K + 07-23 PR + Skovronsky. Intact means: no refuse-to-file of a BLA, no public FDA reaffirmation that analogous-to-protein fails in a way that forces NDA, no CMC slip past Q1 2027. Ricks already flags CMC remaining and "update … as there's any progress on the filing status."

Breaks

  • BLA rejected → NDA slip. District court left FDA room to re-deny "analogous to a protein" with better reasoning. A refuse-to-file on a BLA, or a post-remand FDA designation that retatrutide is a drug, is an NDA path (5-year NCE exclusivity vs 12-year biologic reference exclusivity; compounding exposure differs). Classification delay is the break — not TRIUMPH efficacy.
  • Oral cannibalizes without new patients. Falsifier for the mix test: Foundayo share of starts rises while treated stays a closed injectable pool (no new patients; ASP/volume on Zepbound rolls over). Yuffa's 60–70% new-to-treatment is the current counter; it is early and un-census'd.
  • Bridge stays tiny. Falsifier vs Ricks 20M / 35%: realized Bridge fills stay a rounding error vs 3.8M KFF eligible (or vs CMS "single-digit millions"). No fill census yet, so this break is open, not scored.

Attach, do not flatten (hardware + mechanisms + orexin)

GLP-1 hardware is already marked. Do not copy WST/STVN last-prices, mix, or Gage into this LLY clip.

Gage

Empty. No Gage mark for LLY. Not a trade. Not a paper sleeve. No buy/sell/size. No source URL to invent. Hardware Gage on wst / stevanato stays on those pages.

Contradictions and open questions

  • Bridge denominator: KFF 3.8M Bridge-eligible (2023, after T2D/OSA/MASH/prior-GLP-1 exclusions) vs Lilly/Ricks 20 million eligible Americans + 35% more coverage vs CMS no headcount / Klomp "single-digit millions" (Klomp quoted by KFF, not independently retrieved as a CMS transcript). Wiki currently labels 3.8M as CMS — that is a mis-attribution.
  • Foundayo 25% vs 80%: 1-in-4 is new starts; 80% injectable is people getting treatment (Bridge/inflection Q&A). They are not the same base. Do not write "25% of the franchise is oral."
  • US −3% vs −9% price: Exhibit 99.1: reported US price −3%; ex rebate/discount estimate adjustments, ~−9%. Q3 test should say which print it is using.
  • 7th Circuit argument date: reported in secondary legal blogs; not retrieved from a court calendar. District-court order + Ricks "active litigation" are the load-bearing facts.
  • Actual Bridge fills: none-found. Cannot score "Bridge stays tiny" until CMS or Lilly prints a count.
  • IQVIA weekly Foundayo TRx: not retrieved as a primary for this clip; do not import Fierce/Citi secondary script tallies.

Provenance

Method: Grok Bot / parallel-deep-research / native X Generated: 2026-08-31 Wiki priors read via gh api (no clone): vault/projects/stock-market/wiki/entities/eli-lilly.md (updated 2026-08-06, through Aug 5 Q2; no checkpoint map, no last-price, no Gage); wst.md; stevanato.md; wiki/questions/glp1-surge-to-injectable-supply-chain-bottleneck.md; wiki/mechanisms/orexin-franchise-to-lly-glp1-playbook-repeat.md; vault/projects/stock-market/EARNINGS.md; vault/_meta/CLIPPING_CONTRACT.md.

Web sources:

X sources:

  • none found — user-X search_news returned 403 client-not-enrolled ("When authenticating requests to the X API v2 endpoints, you must use keys and tokens from a developer App that is attached to a Project."). search_posts_all skipped per instruction.

Grokipedia:

  • not used
Referenced by
Mechanisms
GLP-1 demand surge → four-layer manufacturing bottleneck → Bachem / Stevanato / West Pharma / YpsomedGLP-1 efficacy ~ bariatric-surgery-like + Medicare Bridge access → patients substitute drugs for surgery → structural bariatric-surgery volume decline → ISRG bariatric segment down (loser) / LLY obesity TAM up (winner)
Entities
Eli Lilly